Chemical Week Magazine :: Business & Finance :: United States/Americas
Schulman, Ferro prepare for next stage in bid, proxy fight
2:15 PM MDT | April 15, 2013 | —Vincent Valk and Rebecca Coons
Ferro sold its pharmaceuticals business, increased its earnings guidance, and issued a letter to shareholders, while A. Schulman fell short of estimates and amended CEO Joseph Gingo’s contract to extend it in the event of a “transformational acquisition” as the companies hunkered down for the next stage in Schulman’s $855-million hostile bid for Ferro. Gingo’s revised contract provides for a two-year extension, and Schulman specifically mentioned Ferro as the kind of deal that could trigger the extension....
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee